MARKET WIRECNBC • 2h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Why PGEN Stock surged +9.21% Today — RQD Quant Desk Flash
$6.64 +9.21% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $6.74
Precigen Inc. (PGEN) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $2.38B
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $6.74 (+1.47%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (35/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.5% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D- · Rk E
Each axis scored 0–20
12M PRICE TARGET CONE-10.4% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PGEN)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (35/100 Composite)
🔍 WHY PGEN SCORES 35/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+12/20 pts (34% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▲ #2 Bullish Driver: Cash Engine Quality+8/20 pts (23% of score)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$7.81-18.2% Next Q
43
Q2 (-2Q)Grade D$6.39-3.1% Next Q
40
Q3 (-1Q)Grade E$6.19+7.3% Next Q
38
CurrentGrade D-$6.64-8.5% Hist 90D α
35
Trajectory: D (43) → D- (35)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a PGEN Turnaround Squeeze
While PGEN currently carries a cautious 35/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($7.22) and Max Pain ($6.97) forces dealer call-delta covering toward $9.43.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $PGEN• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “PGEN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why PGEN Stock surged +9.21% Today — RQD Quant Desk Flash
Precigen Inc. (PGEN) surged +9.21% to $6.64, trading at 61% of its 52-week range ($3.04 – $8.98). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 61% of its 52-week range ($3.04 – $8.98) with RSI-14 at 50.3 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $6.64 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live PGEN Headlines & Catalysts
MARKET WIRECNBC • 3h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 4h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 5h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 6h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 7h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 7h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
MARKET WIREReuters • 7h ago
German ministers pledge tough action after rioters damage stores in Frankfurt - ReutersGerman ministers pledge tough action after rioters damage stores in Frankfurt Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PGEN)
- ✓Walkthrough of PGEN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
PGEN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +59.62%📐 HORIZONTAL RANGE
2026-10-30O $6.49H $7.04L $6.49C $6.64VOL 7.93M
RES: $9.93SUP: $5.91SMA50: $7.22SMA200: $5.27
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
PGEN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +146.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on PGEN today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for PGEN. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for PGEN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PGEN)
Health Care Rank #808 of 1016
⚔️ HCM vs PGEN Full Matrix →
1. Head-to-Head Health Care Peer Comparison (PGEN vs. HCM, RCUS, PHVS, SUPN)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Precigen Inc. (PGEN) ranks #808 by composite RQD confidence (35/100, grade D-) and #226 by equity capitalization ($2.38B). Within this direct 5-issuer industry benchmark cohort, HCM leads on earnings valuation at 5.2x trailing P/E, while HCM leads on capital efficiency and profitability with -2.5% ROIC and — gross margin. PHVS currently holds the highest overall quantitative score in the immediate peer group at 63/100 (C) compared with PGEN at 35/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| PGEN
ACTIVE
Precigen Inc. | D- | 35/100 | — | — | -35.0% | +9.21% | $2.38B | Benchmark Subject |
| HCM HUTCHMED (China) Limited | D | 46/100 | 5.2x | — | -2.5% | +2.03% | $2.37B | /hcm-vs-pgen → |
| RCUS Arcus Biosciences Inc. | D- | 35/100 | — | — | -35.0% | +1.20% | $2.37B | /rcus-vs-pgen → |
| PHVS Pharvaris N.V. | C | 63/100 | — | — | — | +2.32% | $2.34B | /phvs-vs-pgen → |
| SUPN Supernus Pharmaceuticals Inc. | D+ | 56/100 | — | 89.6% | -4.5% | +1.85% | $2.43B | /supn-vs-pgen → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001356090In its most recent audited fiscal period (FY2025, filed 2025-12-31), Precigen Inc. (PGEN) reported GAAP revenue of $9.7M (+146.7% vs. FY2024 revenue of $3.9M , and +55.6% cumulative change since FY2023) , GAAP net income of -$250.6M, operating cash flow of -$87.8M, and free cash flow of -$89.8M (-17.0% YoY). On the balance sheet, PGEN closed FY2025 with $155.5M in total assets against $93.2M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $9.7M | -$250.6M | -$87.8M | -$89.8M | $155.5M | $93.2M |
| FY2024 (FY) | 2024-12-31 | $3.9M | -$126.2M | -$68.2M | -$76.8M | $145.3M | $0 |
| FY2023 (FY) | 2023-12-31 | $6.2M | -$95.9M | -$66.9M | -$66.9M | — | — |
3. PGEN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs PGEN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Precigen Inc. (NASDAQ: PGEN) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $6.64 (+9.21% 1D, market cap $2.38B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 6/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, PGEN ranks #808 in composite RQD confidence.
How does PGEN compare to HCM and RCUS in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PGEN carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, HCM (HUTCHMED (China) Limited) holds a D grade (46/100 RQD, P/E 5.2x, ROIC -2.5%, cap $2.37B) and RCUS (Arcus Biosciences Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $2.37B). Among the 5-stock peer group, HCM leads on earnings multiple (5.2x) while HCM leads on capital efficiency (-2.5% ROIC).
What are the biggest fundamental strengths and SEC risk factors for PGEN?
Per PGEN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001356090), Precigen Inc. generated $9.7M in revenue (+146.7% YoY), -$250.6M in net income, and -$89.8M in free cash flow against $155.5M in total assets and $93.2M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is PGEN trading relative to its 50-day, 200-day, and 52-week technical levels?
PGEN last traded at $6.64 (+9.21% on volume of 7,742,821 shares), positioning the stock -8.03% below its 50-day simple moving average ($7.22) and +26.00% above its 200-day simple moving average ($5.27). Across its 52-week range of $3.04 to $8.98, PGEN sits at the 60.6% percentile with a 14-day RSI of 50.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($5.81 to $7.47).
PGEN Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is PGEN stock moving today?
Why PGEN Stock surged +9.21% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.